22nd Century Group, Inc. (XXII), a next-generation plant biotechnology company, was featured in a Washington Post article on Tuesday, discussing the U.S. FDA's proposed policy to reduce nicotine content in cigarettes.
The policy, which recently passed a review by the Office of Management and Budget, could benefit an estimated 13 million smokers in its first five years.
The article emphasizes the potential of 22nd Century's VLN reduced nicotine content cigarettes to help smokers control their nicotine intake.
VLN cigarettes are the first and only combustible tobacco products authorized by the FDA under its Modified Risk Tobacco Product designation.
These products, which contain 95% less nicotine than traditional cigarettes, are already available in more than 5,000 stores across the U.S.
Larry Firestone, CEO of 22nd Century, expressed optimism about the FDA's policy, noting that it represents one of the most impactful smoking harm reduction strategies in recent history.
The company continues to expand the availability of its VLN products and aims to demonstrate the effectiveness of reduced nicotine content cigarettes in helping smokers reduce their nicotine consumption.
Currently, XXII is trading at $7.34 up by 20.83%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.